- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nasdaq halts trading of L&H shares
Troubles continue for voice recognition technology provider Lernout & Hauspie (HNN 10/18/00). With the U.S. Securities and Exchange Commission and the Easdaq stock exchange both investigating accusations of questionable accounting practices
Troubles continue for voice recognition technology provider Lernout & Hauspie (HNN 10/18/00). With the U.S. Securities and Exchange Commission and the Easdaq stock exchange both investigating accusations of questionable accounting practices by L&H, Easdaq and Nasdaq have halted trading of the company's shares. Trading will not resume on either exchange until the firm has fully satisfied Nasdaq's request for additional information.
L&H, which is also facing a number of class action lawsuits, is in the process of restating its financial results from the past two and a half years. The beleaguered VR vendor is considering measures including staffing cuts and pulling back product lines to speed its return to profitability.
© 2000 Miller Freeman Inc.
11/29/00, Issue # 117, page 5.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
